IL1B and Alzheimer disease: Bao et al. showed that oral administration of EGCG (50 mg/kg) for 4 months markedly attenuated the cognitive impairments in APP/PS1 transgenic mice used as an AD model, alleviated microglia activation and expression of the proinflammatory cytokine IL-1β, and increased the level of anti-inflammatory cytokines IL-10 and IL-13 [74].